CDC7 激□抑制劑：全球臨床試驗與市場機會 (2024)

CDC7激□最有前途的原因之一是它作為癌症藥物標靶的潛力。癌細胞不受控制的增殖通常涉及 DNA 複製失調，且 CDC7 激□通常在各種癌症類型中過度表達。抑制 CDC7 激□會抑制複製過程，導致 DNA 損傷最終導致細胞死亡。因此，預計靶向 CDC7 激□將能夠阻止癌症進展。CDC7 激□抑制劑專注於抑制 DNA 複製過程，因此有可能提供一種更特異、毒性更小的方法。

除了癌症之外，CDC7激□在發炎和病毒性疾病的治療中也引起了人們的關注。發炎性疾病通常涉及過度的細胞增殖，調節 CDC7 激□可以抑制這種增殖並減輕發炎反應。此外，有些病毒，特別是DNA病毒，利用宿主細胞的DNA複製機制進行自身複製。此外，最近的研究表明，某些病毒（例如阿比病毒屬病毒）使用 CDC7 磷酸化 VP3，從而增強病毒的複製能力。抑制 CDC7 激□有可能阻止病毒複製，從而提供一種新的抗病毒治療方法。

此外，研究表明，將 CDC7 激□抑制劑與現有的癌症化療相結合可能會提高療效。這些治療方法的結合可以解決癌細胞的異質性，並為癌症治療提供全面的解決方案。CDC7 激□在特定癌症類型中的過度表達可以實現個人化的治療方法。這意味著 CDC7 激□過度表達的患者可能會從客製化治療中受益匪淺。

製藥公司已經認識到 CDC7 激□的潛力，並正在積極開發針對該標靶的抑制劑，多項臨床試驗正在進行中。隨著臨床試驗的進展，CDC7激□作為抗癌藥物標靶、抗發炎標靶和抗病毒工具的前景越來越光明。該領域的持續研發有可能徹底改變癌症治療、發炎性疾病治療和抗病毒策略。

本報告探討了 CDC7 激□抑制劑的臨床試驗趨勢和市場機會，總結了按公司、適應症和階段劃分的臨床管道、按國家/地區劃分的趨勢、發展驅動因素和挑戰以及競爭格局。

目錄

第一章 CDC7 激□抑制劑：簡介

第二章全球 CDC7 激□抑制劑市場與臨床趨勢：依適應症分類

• 白血病
• 大腸直腸癌
• 胰臟癌

第三章 全球CDC7抑制劑市場展望

• 當前市場前景
• 未來市場機會

第 4 章 CDC7 激□抑制劑市場趨勢：按地區

• 中國
• 日本
• 英國
• 美國

第五章 全球CDC7蛋白激□抑制劑臨床試驗概況

• 按國家
• 適應症
• 階段
• 治療班

第六章 CDC7蛋白激□抑制劑的全球臨床管線：依公司、適應症和階段分類

• 第一階段
• 一期/二期

第七章全球 CDC7 激□抑制劑市場：市場動態

• 市場驅動力
• 市場挑戰

第八章 競爭格局

• Carna Biosciences
• Chia Tai Tianqing Pharmaceutical Group
• Eli Lilly
• Memorial Sloan-Kettering Cancer Center
• Schrodinger

“Global CDC7 Kinase Inhibitors Clinical Trials & Market Opportunity Insight 2024” Report Highlights:

• Global CDC7 Kinase Inhibitors Clinical Pipeline By Company, Indication & Phase
• Highest Clinical Phase: Phase-I/II
• US Dominating Global CDC7 Kinase Inhibitors Clinical Trials
• Global CDC7 Inhibitors Market Current & Future Outlook
• CDC7 Kinase Inhibitors Development Trends by Country
• Competitive Landscape

Kinase proteins are targets of upmost importance in the realm of cancer therapeutics because of their ubiquitous roles in numerous cell processes. Research on kinases has spanned several decades, and in the process, a large number of kinases have been identified. One of these, discovered in the early 1970s, is the cell division cycle 7-related protein kinase, or the CDC7 kinase protein that is encoded by the CDC7 gene. Similar to other kinase proteins, CDC7 is needed for several cell processes, including replication, which has brought it into the limelight as another targetable protein for the development of cancer chemotherapies. Despite years of studies, researchers are still trying to understand the function and therapeutic potential of CDC7; however, a couple pharmaceutical companies are already making strides in the pharmaceutical market with their CDC7-inhibiting candidates in development and clinical evaluation.

CDC7 is a serine-threonine kinase. Its significance in the replication process was initially demonstrated using mouse embryonic stem cells, where DNA synthesis was inhibited in the absence of CDC7, resulting in the halting of the S phase at the G2-M DNA damage checkpoint to prevent mitosis with the damaged or incomplete DNA. CDC7 is therefore essential for the initiation of DNA replication process, making it a potential target for various therapeutic applications. CDC7 kinase functions in collaboration with tits regulatory subunit DBF4, forming the CDC7-DBF4 complex. This complex helps regulate the formation of the DNA replication origins, ensuring proper DNA replication and cell division.

One of the most promising aspects of CDC7 kinase is its potential as a cancer drug target. The uncontrolled proliferation of cancer cells often involves dysregulation of DNA replication, and CDC7 kinase is often overexpressed in various cancer types. Inhibition of CDC7 kinase can disrupt the replication process, leading to DNA damage and ultimately, cell death. As a result, targeting CDC7 kinase holds great promise in halting the progression of cancer. Traditional cancer therapies, such as chemotherapy and radiation, target rapidly dividing cells. In contrast, CDC7 kinase inhibitors focus on disrupting DNA replication process, offering a more specific and potentially less toxic approach.

Beyond cancer, CDC7 kinase is also gaining attention for its role in treating inflammatory and viral diseases. Inflammatory diseases often involve excessive cell proliferation, and the modulation of CDC7 kinase can potentially reduce this proliferation, mitigating the inflammatory response. Additionally, some viruses, particularly DNA viruses, reply on host cell DNA replication machinery for their own replication. Moreover, in a recently conducted study, it was shown that certain viruses, like Avibirnavirus, use the CDC7 to phosphorylate the VP3, enhancing the replication ability of the virus. By inhibiting CDC7 kinase, it may be possible to thwart viral replication, offering a new approach in antiviral therapies.

Inhibition of CDC7 offers potential benefits over other cancer therapies. The CDC7 kinase is involved in the DNA replication initiation, and inhibiting it is expected to have minimal off-target interactions, compared to other broadly targeted therapies. In addition, combining CDC7 kinase inhibitors with existing cancer chemotherapies has shown potential for enhanced efficacy in research studies. The combination of these therapies may provide a comprehensive solution to cancer treatment, addressing the heterogeneity of cancer cells. The overexpression of CDC7 kinase in specific cancer types allows for a personalized approach to treatment. So, patients with CDC7 kinase overexpression could benefit significantly from tailored therapies.

Pharmaceutical companies have recognized the potential of CDC7 kinase and are actively developing inhibitors for this target, with a few clinical trials. As clinical trials progress, the future of CDC7 kinase as a cancer drug target, anti-inflammatory target, and antiviral tool is becoming increasingly promising. The continued research and development in this field hold the potential to revolutionize cancer therapy, inflammatory disease treatment and antiviral strategies.

CDC7 kinase is developing as an intriguing player in the pharmaceutical sector, with substantial potential in the treatment of cancer, inflammatory processes, and viral diseases. Its specificity, synergy with existing therapies, and personalized treatment options make it a compelling choice for researchers and clinicians alike. As pharmaceutical companies invest in the development of CDC7 kinase inhibitors, the coming years look bright for this remarkable protein kinase, paving the way for innovative and effective therapeutic options.

Table of Contents

1. Brief Introduction To CDC7 Kinase Inhibitors

• 1.1. Overview
• 1.2. History & Emergence of CDC7 Kinase Inhibitors

2. Global CDC7 Kinase Inhibitors Market & Clinical Trends by Indications

• 2.1. Leukemia
• 2.2. Colorectal Cancer
• 2.3. Pancreatic Cancer

3. Global CDC7 Inhibitors Market Outlook

• 3.1. Current Market Outlook
• 3.2. Future Market Opportunity

4. CDC7 Kinase Inhibitors Market Trend By Region

• 4.1. China
• 4.2. Japan
• 4.3. UK
• 4.4. US

5. Global CDC7 Protein Kinase Inhibitors Clinical Trials Overview

• 5.1. By Country
• 5.2. Indication
• 5.3. Phase
• 5.4. Therapy Class

6. Global CDC7 Protein Kinase Inhibitors Clinical Pipeline By Company, Indication & Phase

• 6.1. Phase-I
• 6.2. Phase-I/II

7. Global CDC7 Kinase Inhibitor Market Dynamics

• 7.1. Market Drivers
• 7.2. Market Challenges

8. Competitive Landscape

• 8.1. Carna Biosciences
• 8.2. Chia Tai Tianqing Pharmaceutical Group
• 8.3. Eli Lilly
• 8.4. Memorial Sloan-Kettering Cancer Center
• 8.5. Schrodinger

List of Figures

• Figure 1-1: CDC7 Kinase Inhibitor - Mechanism of Action
• Figure 1-2: Comparison of CDC7 Inhibitors With Conventional Methods
• Figure 1-3: CDC7 Inhibitor Development
• Figure 2-1: LBS-007 Phase I/II Study - Initiation & Completion Year
• Figure 2-2: Schrodinger Drug Discovery Approach
• Figure 2-3: SGR-2921 Phase I Study - Initiation & Completion Year
• Figure 2-4: TAK-931 Phase II Trials Commencement
• Figure 2-5: Ongoing CDC7 Inhibitors Candidates - Mode Of Action
• Figure 2-6: LY3143921 hydrate Phase I Study - Initiation & Completion Year
• Figure 2-7: TQB3824 Phase I Study - Initiation & Completion Year
• Figure 2-8: CDC7 Inhibitor For The Treatment Of Pancreatic Cancer
• Figure 3-1: Global CDC7 Inhibitor - Current Ongoing Candidates In Trials
• Figure 3-2: Global CDC7 Inhibitors Market - Future Aspects
• Figure 4-1: Candidates Developed By Nerviano Medical Science
• Figure 4-2: Aspects For The Inclining Growth Of CDC7 Inhibitors In China
• Figure 4-3: AS-0141: Mechanism Of Action
• Figure 4-4: Timeline Of AS-0141
• Figure 4-5: Ongoing Research Conducted By Cancer Research Horizon
• Figure 4-6: US - Cancer Incidences & Deaths, 2023
• Figure 5-1: Global - CDC7 Protein Kinase Inhibitors Clinical Trials by Country (Numbers), 2023 & 2024
• Figure 5-2: Global - CDC7 Protein Kinase Inhibitors Clinical Trials by Indication (Numbers), 2023 & 2024
• Figure 5-3: Global - CDC7 Protein Kinase Inhibitors Clinical Trials by Phase (Numbers), 2023 & 2024
• Figure 5-4: Global - CDC7 Protein Kinase Inhibitors Clinical Trials by Therapy Class (Numbers), 2023 & 2024
• Figure 7-1: Global - CDC7 Inhibitor Market Drivers
• Figure 7-2: Global - CDC7 Inhibitor Market Challenges

List of Tables

• Table 2-1: Leukemia Cancer - CDC7 Kinase Inhibitor Ongoing Clinical Trials
• Table 2-2: Colorectal Cancer - CDC7 Kinase Inhibitor Ongoing Clinical Trials
• Table 2-3: Pancreatic Cancer - CDC7 Kinase Inhibitor Ongoing Clinical Trials
• Table 4-1: China - CDC7 Kinase Inhibitor Ongoing Preclinical & Clinical Trials
• Table 4-2: Japan - CDC7 Kinase Inhibitor Ongoing Clinical Trials
• Table 4-3: UK - CDC7 Kinase Inhibitor Ongoing Clinical Trials